Fierce Pharma2d
Paratek acquires Optinose, rhinosinusitis spray Xhance in deal worth up to $330M
In a move to expand its portfolio beyond antibiotics, Paratek Pharmaceuticals has bought out Optinose and its chronic ...
Paratek Pharmaceuticals to Acquire Optinose, Creating Significant Commercial Expansion Opportunities for XHANCE® in Chronic Rhinosinusitis (CRS)
Paratek will accelerate access for XHANCE beyond specialists to primary care providers maximizing the recent label expansion for CRS in a ...
Zacks Investment Research on MSN23h
OPTN Stock Soars 53% on Inking $330M Deal to be Acquired by Paratek
Shares of OptiNose OPTN soared 52.5% on Thursday after the company announced that it is set to be acquired by Paratek ...
Stocktwits on MSN2d
Optinose Shares Soar After Merger Agreement With Paratek Pharmaceuticals: Retail Sentiment Takes Flight
Shares of Optinose, Inc. (OPTN) rocketed about 55% on Thursday after privately held Paratek Pharmaceuticals announced that it ...
Endpoints News2d
Paratek boosts com­mer­cial port­fo­lio in move to buy Opti­nose and its nasal spray
Paratek Pharmaceuticals to acquire Optinose and its nasal drug-device Xhance for up to $330M, expanding beyond antibiotics ...
Paratek Pharmaceuticals to acquire Optinose in $330M transaction
Paratek Pharmaceuticals (PRTK) and Optinose (OPTN) announced they have entered into a definitive merger agreement under which Paratek will ...
Marketing Dive13y
RIM acquires Paratek to help refresh BlackBerry
RIM's acquisition of Paratek and its RF tuning technologies plays to its strengths ? enabling broad connectivity for business users,? said Rich Karpinski, senior analyst for mobility at Yankee Group, ...
Morningstar2d
Paratek Pharmaceuticals to Acquire Optinose, Creating Significant Commercial Expansion Opportunities for XHANCE® in Chronic Rhinosinusitis (CRS)
BOSTON and YARDLEY, Pa., March 19, 2025 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals and Optinose, Inc. (NASDAQ:OPTN) today announced they have entered into a definitive merger agreement under ...